Every 8-K that IQVIA Holdings Inc. (IQV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IQV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IQV filings page.
IQVIA HOLDINGS INC. (IQV) reported that its wholly owned subsidiary, IQVIA Inc., has priced a private offering of $2,000,000,000 aggregate principal amount of senior notes due March 15, 2034, bearing interest at 6.375% per annum and paying semi-annual interest starting March 15, 2027.
The company plans to use the net proceeds to redeem in full its existing Senior 5.000% Notes due 2026, repay a portion of the outstanding indebtedness under its revolving credit facility, and pay fees and expenses related to the notes offering. The issuance of the notes is expected to occur on or about September 23, 2026, subject to customary closing conditions, and is being conducted as a private offering under Rule 144A and Regulation S.
IQVIA Holdings reported strong second‑quarter 2026 results, with revenue of $4,368 million, up 8.7% year-over-year, and segment revenue of $1,793 million in Commercial Solutions and $2,575 million in Research & Development Solutions. R&DS delivered record net new bookings of $3.15 billion, a 19% increase and a 1.22x book‑to‑bill ratio, supporting a contracted backlog of $34.2 billion.
GAAP net income was $256 million, or $1.53 diluted EPS. Adjusted EBITDA reached $994 million, up 9.2%, and Adjusted Diluted EPS was $3.15, up 12.1% year-over-year. Operating cash flow rose to $558 million and Free Cash Flow to $360 million. The company repurchased $398 million of stock in the quarter, with $2,819 million authorization remaining and a net leverage ratio of 3.59x.
On the back of this performance, IQVIA raised its full‑year 2026 guidance, now expecting revenue between $17,275 million and $17,475 million, Adjusted EBITDA between $4,000 million and $4,050 million, and Adjusted Diluted EPS between $12.80 and $13.00, reflecting a higher 6.5% revenue growth midpoint versus 5.8% previously.
IQVIA Holdings Inc. reported that its wholly owned subsidiary IQVIA Inc. issued €950,000,000 of 4.625% senior notes due 2033. These unsecured notes provide long-term euro-denominated funding. Interest is payable semi-annually on June 15 and December 15, beginning December 15, 2026.
The notes mature on June 15, 2033, unless earlier repurchased or redeemed under their terms. IQVIA plans to use the net proceeds to refinance certain existing indebtedness and to pay related fees and expenses, effectively replacing older debt with this new issue.
The notes were issued under an Indenture dated June 11, 2026, among IQVIA Inc. as issuer, U.S. Bank Trust Company, National Association as trustee, and certain subsidiaries as guarantors. The issuer may redeem the notes before maturity, including a make-whole premium before June 15, 2029, and thereafter at a redemption premium that declines from 2.313% to 0%.
IQVIA Holdings Inc. announced that its subsidiary, IQVIA Inc., has priced an offering of €950,000,000 in senior notes due 2033. The notes will bear interest at 4.625% per annum, paid semi-annually on June 15 and December 15, starting December 15, 2026, and will mature on June 15, 2033 unless earlier repurchased or redeemed. IQVIA plans to use the proceeds to refinance certain existing indebtedness and to pay fees and expenses related to the transaction. The issuance is expected to close on or about June 11, 2026, subject to customary closing conditions, and the notes are being sold in a private offering to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S.
IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., plans to raise €950,000,000 through an offering of senior notes due 2033. The company expects to use the proceeds to refinance certain existing indebtedness and to pay related fees and expenses.
The notes will not be registered under the Securities Act and will be offered privately to qualified institutional buyers in the United States under Rule 144A and to non-U.S. investors under Regulation S. Completing the offering is subject to market and other customary conditions and is not yet assured.
IQVIA Holdings Inc. announced that its board of directors approved an additional $2 billion share repurchase authorization under its existing equity repurchase program, bringing the total remaining authorization to $3.2 billion. The program has no expiration date and does not require IQVIA to repurchase any specific amount of stock.
Repurchases may be made in open market transactions, block trades, or privately negotiated deals, and can be modified, extended, suspended or discontinued at any time based on IQVIA’s share price, corporate needs and overall market conditions.
IQVIA Holdings Inc. reported strong first-quarter 2026 results, with revenue of $4,151 million, up 8.4% year-over-year, driven by both Commercial and R&D Solutions. Commercial Solutions revenue grew 11.6% to $1,754 million, while Research & Development Solutions reached $2,397 million, up 6.2%.
GAAP net income was $274 million with diluted EPS of $1.61. Adjusted EBITDA rose to $932 million, and Adjusted Diluted EPS increased to $2.90, up 7.4% year-over-year. Free Cash Flow was $491 million, up 15% and equal to 100% of Adjusted Net Income.
R&D Solutions contracted backlog was $34.2 billion, with about $8.9 billion expected to convert to revenue in the next twelve months and a book-to-bill of 1.04x. The company repurchased $552 million of stock and reaffirmed 2026 revenue and Adjusted EBITDA guidance while raising Adjusted Diluted EPS guidance to $12.65–$12.95.
IQVIA Holdings Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved the new 2026 Incentive and Stock Award Plan, which replaces the 2017 plan and supports a wide range of equity awards tied to performance measures such as revenue, adjusted EBITDA and relative total stockholder return.
As of the February 23, 2026 record date, 167,866,339 common shares were outstanding and entitled to vote. All nominated directors were elected. The advisory vote on 2025 executive compensation passed with 118,398,355 votes for and 29,398,856 against. Shareholders approved the 2026 Plan with 96,987,612 votes for and 51,006,455 against, and ratified PricewaterhouseCoopers LLP as auditor with 140,865,227 votes for. A stockholder proposal to separate the Chairman and CEO roles did not pass, receiving 36,717,802 votes for and 111,154,252 against.
IQVIA Holdings Inc. filed a current report to let investors know it released its financial results for the fourth quarter and full year ended December 31, 2025. The company announced these results through a press release dated February 5, 2026.
The press release is available on IQVIA’s website and is furnished as Exhibit 99.1 to this report. The company notes that this information is being furnished, not filed, meaning it is not subject to certain liability provisions of the Securities Exchange Act and is not automatically incorporated into other securities filings.
IQVIA Holdings Inc. reported that it entered into an amendment to its Fifth Amended and Restated Credit Agreement. The amendment refinances existing Term A-1 and Term A-2 dollar term loans into a new class of term A dollar loans, and refinances existing term A euro loans into a new class of term A euro loans. It also consolidates all current U.S., Japanese, and Swiss/Multicurrency revolving credit commitments into a new class of revolving credit commitments.
The amendment reduces the interest rate on term A loans and revolving credit loans denominated in U.S. dollars by eliminating the term SOFR credit spread adjustment. In addition, the Swiss Subsidiary Borrower and the Japanese Borrower are released from all obligations as borrowers under the credit agreement.
IQVIA Holdings Inc. appointed William G. Kaelin Jr., M.D. to its Board of Directors on November 5, 2025. The Board determined that Dr. Kaelin meets the New York Stock Exchange definition of an independent director. In connection with the appointment, he is expected to enter into the company’s standard indemnification agreement for non-management directors and will participate in the non-employee director compensation program described under “Director Compensation” in the proxy statement dated February 28, 2025. The company announced the appointment via a press release attached as Exhibit 99.1.
IQVIA Holdings Inc. furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The full text of the release was posted on the company’s website and is included as Exhibit 99.1. Pursuant to General Instruction B.2, the Item 2.02 information is furnished, not filed, and is not subject to Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced.
IQVIA Holdings Inc. appointed Michael J. Fedock as its next Executive Vice President and Chief Financial Officer, effective February 28, 2026, as part of a planned CFO succession. He will succeed Ronald E. Bruehlman, who will retire from the CFO role on that date and become Senior Advisor to the CEO to support a smooth transition.
Mr. Fedock has more than 25 years of healthcare industry experience and has held several senior finance roles at IQVIA since 2016, including Senior Vice President, Financial Planning and Analysis, and CFO roles for key business units. In connection with his promotion, his annual base salary will increase to $750,000, and he will have an annual cash incentive target equal to 100% of base salary, along with eligibility for long-term incentives under IQVIA’s 2017 Incentive and Stock Award Plan and standard executive benefit plans.